10x Genomics Q2 FY26 net loss widens to $17.93 million; revenue falls to $151.04 million - TXG News | Rallies10x Genomics Q2 FY26 net loss widens to $17.93 million; revenue falls to $151.04 million
T
TXG• Q2 results and full-year outlook
- 10x Genomics Q2 revenue fell to $151 million; excluding $1.6 million from a patent settlement, revenue rose 3% from Q2 2025.
- Net results turned to a loss of $17.9 million; operating results swung to a loss of $19.6 million.
- Gross margin widened 2 percentage points to 74%, due to lower manufacturing costs including $2.6 million of tariff refunds.
- Operating expenses climbed 39% to $132.1 million, reflecting a smaller settlement gain versus the year-ago quarter.
- Raised 2026 revenue outlook to $610 million-$630 million; highlighted strong early order flow for Atera, acquired Proteintech Genomics.
•
